Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 59.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,944 shares of the company’s stock after acquiring an additional 1,099 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Apellis Pharmaceuticals were worth $75,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of APLS. Assenagon Asset Management S.A. purchased a new position in shares of Apellis Pharmaceuticals in the 1st quarter valued at about $6,025,000. Victory Capital Management Inc. boosted its holdings in Apellis Pharmaceuticals by 21.7% during the first quarter. Victory Capital Management Inc. now owns 1,688,663 shares of the company’s stock valued at $32,929,000 after purchasing an additional 300,900 shares in the last quarter. Regent Investment Management LLC acquired a new stake in Apellis Pharmaceuticals during the second quarter valued at approximately $591,000. Bailard Inc. acquired a new stake in Apellis Pharmaceuticals during the first quarter valued at approximately $254,000. Finally, Bank of America Corp DE boosted its holdings in Apellis Pharmaceuticals by 146.0% during the fourth quarter. Bank of America Corp DE now owns 17,533 shares of the company’s stock valued at $231,000 after purchasing an additional 10,407 shares in the last quarter. Hedge funds and other institutional investors own 63.76% of the company’s stock.
APLS has been the topic of a number of recent research reports. Cowen set a $40.00 price objective on Apellis Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, July 31st. Oppenheimer assumed coverage on shares of Apellis Pharmaceuticals in a research note on Tuesday, July 9th. They set an “outperform” rating and a $52.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $50.00 price target (down previously from $52.00) on shares of Apellis Pharmaceuticals in a research note on Thursday, August 1st. ValuEngine downgraded shares of Apellis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research downgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. Apellis Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $45.14.
APLS traded down $0.11 during midday trading on Thursday, hitting $29.85. The company had a trading volume of 14,254 shares, compared to its average volume of 334,382. Apellis Pharmaceuticals Inc has a 52 week low of $11.45 and a 52 week high of $30.25. The company has a quick ratio of 8.67, a current ratio of 8.67 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -12.64 and a beta of 0.75. The stock’s 50 day moving average price is $27.52 and its 200 day moving average price is $20.99.
Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Wednesday, July 31st. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.18). Research analysts predict that Apellis Pharmaceuticals Inc will post -4 EPS for the current year.
Apellis Pharmaceuticals Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Further Reading: Technical Analysis of Stocks and What It Means
Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals Inc (NASDAQ:APLS).
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.